The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1013
November 7, 1997
View Complete Issue         Table of Contents 2019 
Mibefradil--A New Calcium-Channel Blocker
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Mibefradil--A New Calcium-Channel Blocker
November 7, 1997 (Issue: 1013)
Mibefradil dihydrochloride (Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as the first T-type calcium-channel blocker...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Mibefradil--A New Calcium-Channel Blocker
Article code: 1013a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.